Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itraconazole and rifampin effects on selpercatinib pharmacokinetics in healthy volunteers
NCT05338489Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2018
- Primary completion
- Jul 2018
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label trial of selpercatinib (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration-time Curve, From Time 0 to the Last Observed Non-zero Concentration at 168 hours, Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity at 168 hours and 7 more. Started May 2018; status: completed.
02
Drugs
selpercatinib
Beyond the preview
Go deeper on NCT05338489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05338489.